Specifically, the levels of NDC80 were only decreased in acute myeloid leukemia (LAML) and prostate adenocarcinoma (PRAD) (Figure 1B), and NUF2 downregulation was only observed in LAML and testicular germ cell tumors (TGCT) (Figure 1C). This evidence concerns the gene NDC80 and prostate adenocarcinoma.